Zealand Pharma — September 2022

[hanfrank12]

“We are very pleased to present the compelling results from the Phase 3 study of dasiglucagon in newborns and infants up to 12 months of age at ESPE 2022. This study deepens our understanding of dasiglucagon’s potential as an innovative treatment for CHI patients,” said David Kendall, M.D., Chief Medical Officer of Zealand Pharma. "Zealand is committed to addressing the unmet needs of children living with CHI and we look forward to engaging with regulatory authorities and submitting a New Drug A

[hanfrank12]

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting...

[ProinvestorNEWS]

https://www.proinvestor.com/boards/106186

[YPE]

Er det ikke godt nyt?

[Stroka]

Det var ventet. Indikationen er desuden meget lille.

[SMADK]

https://medwatch.dk/Medicinal___Biotek/article14387129.ece

[LP90]

var det ikke positivt det der er kommet frem ? nu 7% nede

[exitnu]

Endnu et grønt flueben til Zealand Pharma

[YPE]

Jeg synes ikke det er så positivt, at den falder 7%? Jeg er glad for, at jeg satsede mine penge et andet sted i dag.

[Svingtraderen]

Berlingske: https://finans.dk/erhverv/ECE14423705/skaebnetime-for-dansk-biotekselskab-det-er-et-meget-vigtigt-resultat/

[Svingtraderen]

og Medwatch: https://medwatch.dk/Medicinal___Biotek/article14425346.ece?utm_source=Feed&utm_medium=latest

[exitnu]

Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)

https://www.globenewswire.com/news-release/2022/09/21/2520159/0/en/Zealand-Pharma-Announces-Oral-Presentation-of-Phase-2-Data-for-BI-456906-at-the-58th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes-EASD.html

*BI 456906 effectively lowered HbA1c up to -1.88% at week 16 in patients with type 2 diabetes in the Phase

[exitnu]

“We are delighted with the data presented at EASD from Boehringer Ingelheim’s Phase 2 trial of the dual glucagon/GLP-1 receptor agonist BI 456906 that showed effective lowering of HbA1c of up to -1.88% in people with type 2 diabetes at 16 weeks compared to -1.47% observed following open-label treatment with the GLP-1 receptor agonist semaglutide,” said David Kendall, MD, Chief Medical Officer of Zealand Pharma.

[exitnu]

[hanfrank12]

Zealand Pharma har afgørende data klar om få uger. Zealand Pharma har afsluttet sit fase 3-forsøg med lægemiddelkandidaten glepaglutid og venter nu på de afgørende data, så de kan deles med offentligheden.
Det skriver Finans. https://medwatch.dk/Medicinal___Biotek/article14425346.ece?utm_campaign=MedWatch Morgen&utm_content=2022-09-22&utm_medium=email&utm_source=medwatch

[exitnu]

D.d. anslået bagkant vedr. SBS.: 5 handelsdage.

[YPE]

Det bliver vildt spændende at se. Jeg håber på positive resultater, selvom jeg ingen aktier har i virksomheden. God weekend.

[YPE]

Jeg tror dog, at bagkanten er nået. Jeg tror, at der kommer en pressemeddelelse ila. næste uge, hvis ikke allerede i den her weekend.

[YPE]

Flot stigning i dag.

[exitnu]

Den generelle markedsnedtur presser igen Modelporteføljen:

https://ugebrev.dk/life-science/den-generelle-markedsnedtur-presser-igen-modelportefoeljen/

... også lidt omkring Zealand Pharma.